Amgen is trading 5.5% higher at $429.45 in pre-market, with the cause unconfirmed. - Available search results identify no fresh October 2 company announcement explaining the move. - Positive Sjögren’s trial news dates to September 22 and is not a confirmed new catalyst. - A broader biotech-sector decline was reported, but does not explain Amgen’s sharp move higher.